These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
649 related articles for article (PubMed ID: 20435227)
1. Clinical assessment incorporating a personal genome. Ashley EA; Butte AJ; Wheeler MT; Chen R; Klein TE; Dewey FE; Dudley JT; Ormond KE; Pavlovic A; Morgan AA; Pushkarev D; Neff NF; Hudgins L; Gong L; Hodges LM; Berlin DS; Thorn CF; Sangkuhl K; Hebert JM; Woon M; Sagreiya H; Whaley R; Knowles JW; Chou MF; Thakuria JV; Rosenbaum AM; Zaranek AW; Church GM; Greely HT; Quake SR; Altman RB Lancet; 2010 May; 375(9725):1525-35. PubMed ID: 20435227 [TBL] [Abstract][Full Text] [Related]
2. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136 [TBL] [Abstract][Full Text] [Related]
4. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236 [TBL] [Abstract][Full Text] [Related]
5. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746 [TBL] [Abstract][Full Text] [Related]
6. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126 [TBL] [Abstract][Full Text] [Related]
7. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199 [TBL] [Abstract][Full Text] [Related]
8. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. Ross KA; Bigham AW; Edwards M; Gozdzik A; Suarez-Kurtz G; Parra EJ J Hum Genet; 2010 Sep; 55(9):582-9. PubMed ID: 20555338 [TBL] [Abstract][Full Text] [Related]
9. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253 [TBL] [Abstract][Full Text] [Related]
10. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411 [TBL] [Abstract][Full Text] [Related]
11. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Ciccacci C; Falconi M; Paolillo N; Oteri F; Forte V; Novelli G; Desideri A; Borgiani P Pharmacogenet Genomics; 2011 Jun; 21(6):344-6. PubMed ID: 21451434 [TBL] [Abstract][Full Text] [Related]
14. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820 [TBL] [Abstract][Full Text] [Related]
15. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Sagreiya H; Berube C; Wen A; Ramakrishnan R; Mir A; Hamilton A; Altman RB Pharmacogenet Genomics; 2010 Jul; 20(7):407-13. PubMed ID: 20442691 [TBL] [Abstract][Full Text] [Related]